Evidence map›Paper›PMID 41484372›Full record

ReviewThe EMBO journal2026

The expanding roles of homologous recombination proteins in genome stability.

Lorenzo Sassi, Andrea Martinez Marroquin, Salli Waked, Alessandra Ardizzoia, Vincenzo Costanzo

Abstract readReview
In one paragraph

Review in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lorenzo SassiIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0009-0000-5149-8273
Andrea Martinez MarroquinIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0009-0005-6362-224X
Salli WakedIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0009-0008-4710-3943
Alessandra ArdizzoiaIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0009-0004-1809-2684
Vincenzo CostanzoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy. Vincenzo.Costanzo@ifom.eu.ORCID 0000-0002-2920-9508

Funding

Fondazione AIRC per la ricerca sul cancro ETS (AIRC) AIRC fellowship Italy Pre-Doc #31406Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG 2023-ID.28725
6 · The paper itself

Abstract

Homologous recombination (HR) is traditionally portrayed as a DNA double-strand break repair pathway. However, emerging evidence positions RAD51, its partners BRCA1, BRCA2, and other HR factors at the core of a broader genome-maintenance network that operates by a "prevent and protect" strategy extending beyond repair. Here, we review how RAD51 can shield DNA from nucleolytic processing mediated by MRE11 and related nucleases, promote fork reversal, suppress replicative DNA gaps accumulation, and bind abasic sites, averting their conversion into cytotoxic intermediates. These extended functions counteract endogenous replication stress as shown in BRCA1- or BRCA2-deficient contexts, where failure to prevent gaps, protect forks, and safeguard abasic DNA accelerates genomic instability. The functional impairment of HR proteins, which interface with base-excision repair and translesion synthesis, rewires these pathways, driving distinctive base-substitution mutational signatures of HR-defective tumors. Abasic sites, especially from methyl-cytosine metabolism, put replication forks at risk of breaking, amplifying the need for RAD51-mediated defense. Such redefinition of homologous recombination protein function as part of an anticipatory surveillance and protective system, rather than a repair-only module, bears important implications for understanding tumorigenesis, therapy resistance, and aging.

Indexed as

Genomic InstabilityHomologous RecombinationRad51 RecombinaseAnimalsBRCA1 ProteinBRCA2 ProteinDNA RepairDNA ReplicationHumansMRE11 Homologue ProteinBRCA1 ProteinBRCA2 ProteinMRE11 Homologue ProteinRad51 RecombinaseAbasic SitesBRCA2MRE11RAD51Replication Fork Protection

Identifiers

PMID41484372
PMCPMC12864759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.